The association of body mass index with long-term clinical outcomes after ticagrelor monotherapy following abbreviated dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a prespecified sub-analysis of the GLOBAL LEADERS Trial

[1]  J. Mitchell,et al.  Dual antiplatelet therapy in cardiovascular disease: does aspirin increase clinical risk in the presence of potent P2Y12 receptor antagonists? , 2010, Heart.

[2]  M. Cattaneo,et al.  Inhibition of the platelet P2Y12 receptor for adenosine diphosphate does not impair the capacity of platelet to synthesize thromboxane A2. , 2016, European heart journal.

[3]  D. Angiolillo.  Variability in responsiveness to oral antiplatelet therapy. , 2009, The American journal of cardiology.

[4]  V. Montori,et al.  Association of bodyweight with total mortality and with cardiovascular events in coronary artery disease: a systematic review of cohort studies , 2006, The Lancet.

[5]  Craig J. Beavers,et al.  Obesity and Antiplatelets-Does One Size Fit All? , 2015, Thrombosis research.

[6]  P. Morange,et al.  Benefit of Switching Dual Antiplatelet Therapy After Acute Coronary Syndrome According to On-Treatment Platelet Reactivity: The TOPIC-VASP Pre-Specified Analysis of the TOPIC Randomized Study. , 2017, JACC. Cardiovascular interventions.

[7]  S. Larsson.  Causal association between adiposity and cardiovascular disease. , 2019, European heart journal.

[8]  K. Alexander,et al.  The obesity paradox, extreme obesity, and long-term outcomes in older adults with ST-segment elevation myocardial infarction: results from the NCDR , 2017, European heart journal. Quality of care & clinical outcomes.

[9]  R. DeFronzo,et al.  Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial. , 2015, JAMA.

[10]  P. Serruys,et al.  Impact of recruitment and retention on all-cause mortality in a large all-comers randomised controlled trial: insights from the GLOBAL LEADERS trial , 2019, Clinical Research in Cardiology.

[11]  J. Iqbal,et al.  Study of Two Dose Regimens of Ticagrelor Compared With Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention for Stable Coronary Artery Disease , 2018, Circulation.

[12]  A. Loundou,et al.  Clinical implications of very low on-treatment platelet reactivity in patients treated with thienopyridine: the POBA study (predictor of bleedings with antiplatelet drugs). , 2013, JACC. Cardiovascular interventions.

[13]  M. Schulze,et al.  General and abdominal adiposity and risk of death in Europe. , 2008, The New England journal of medicine.

[14]  R. Storey,et al.  The central role of the P2T receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity , 2000, British journal of haematology.

[15]  K. Dickstein,et al.  Mean BMI, visit-to-visit BMI variability and BMI changes during follow-up in patients with acute myocardial infarction with systolic dysfunction and/or heart failure: insights from the High-Risk Myocardial Infarction Initiative , 2019, Clinical Research in Cardiology.

[16]  Marco Valgimigli,et al.  Standardized Bleeding Definitions for Cardiovascular Clinical Trials: A Consensus Report From the Bleeding Academic Research Consortium , 2011, Circulation.

[17]  Marc P. Bonaca,et al.  Pharmacokinetic–pharmacodynamic modelling of platelet response to ticagrelor in stable coronary artery disease and prior myocardial infarction patients , 2018, British journal of clinical pharmacology.

[18]  R. Storey,et al.  Impact of Aspirin Dosing on the Effects of P2Y12 Inhibition in Patients with Acute Coronary Syndromes , 2014, Journal of Cardiovascular Translational Research.

[19]  J. McMurray,et al.  Statistical Controversies in Reporting of Clinical Trials: Part 2 of a 4-Part Series on Statistics for Clinical Trials. , 2015, Journal of the American College of Cardiology.

[20]  G. Montalescot,et al.  Slow response to clopidogrel predicts low response. , 2010, Journal of the American College of Cardiology.

[21]  J. Mitchell,et al.  COX isoforms in the cardiovascular system: understanding the activities of non-steroidal anti-inflammatory drugs , 2006, Nature Reviews Drug Discovery.

[22]  A. Siegbahn,et al.  Fibrin clot properties independently predict adverse clinical outcome following acute coronary syndrome: a PLATO substudy , 2018, European heart journal.

[23]  H. Gurm,et al.  The impact of body mass index on short- and long-term outcomes inpatients undergoing coronary revascularization. Insights from the bypass angioplasty revascularization investigation (BARI). , 2002, Journal of the American College of Cardiology.

[24]  R. Beigel,et al.  Aspirin withdrawal in patients treated with ticagrelor presenting with non‐ST elevation myocardial infarction , 2018, Journal of thrombosis and haemostasis : JTH.

[25]  N. Weissman,et al.  The impact of obesity on the short-term and long-term outcomes after percutaneous coronary intervention: the obesity paradox? , 2002, Journal of the American College of Cardiology.

[26]  Deepak L. Bhatt,et al.  Benefit and Risks of Aspirin in Addition to Ticagrelor in Acute Coronary Syndromes: A Post Hoc Analysis of the Randomized GLOBAL LEADERS Trial. , 2019, JAMA cardiology.

[27]  P. Serruys,et al.  Efficacy and Safety of Ticagrelor Monotherapy in Patients Undergoing Multivessel PCI. , 2019, Journal of the American College of Cardiology.

[28]  P. Scherer,et al.  Adipose tissue, inflammation, and cardiovascular disease. , 2005, Circulation research.

[29]  P. Serruys,et al.  Ascertainment of Silent Myocardial Infarction in Patients Undergoing Percutaneous Coronary Intervention (from the GLOBAL LEADERS Trial). , 2019, The American journal of cardiology.

[30]  Dick M. Goedhart,et al.  The impact of body mass index on the one year outcomes of patients treated by percutaneous coronary intervention with Biolimus- and Sirolimus-eluting stents (from the LEADERS Trial). , 2010, The American journal of cardiology.

[31]  Mandeep Singh,et al.  An updated bleeding model to predict the risk of post-procedure bleeding among patients undergoing percutaneous coronary intervention: a report using an expanded bleeding definition from the National Cardiovascular Data Registry CathPCI Registry. , 2013, JACC. Cardiovascular interventions.

[32]  A. Kastrati,et al.  Impact of body mass index on platelet aggregation after administration of a high loading dose of 600 mg of clopidogrel before percutaneous coronary intervention. , 2007, The American journal of cardiology.

[33]  Akshay S. Desai,et al.  2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials. , 2018, Journal of the American College of Cardiology.

[34]  P. Serruys,et al.  Impact of long-term ticagrelor monotherapy following 1-month dual antiplatelet therapy in patients who underwent complex percutaneous coronary intervention: insights from the Global Leaders trial. , 2019, European heart journal.

[35]  S. Oparil,et al.  Changes in cardiovascular risk associated with phentermine and topiramate extended-release in participants with comorbidities and a body mass index ≥27 kg/m(2). , 2013, The American journal of cardiology.

[36]  A. Zaman,et al.  The Relationship of Body Mass Index to Percutaneous Coronary Intervention Outcomes: Does the Obesity Paradox Exist in Contemporary Percutaneous Coronary Intervention Cohorts? Insights From the British Cardiovascular Intervention Society Registry. , 2017, JACC. Cardiovascular interventions.

[37]  P. Serruys,et al.  Ticagrelor Alone Versus Dual Antiplatelet Therapy From 1 Month After Drug-Eluting Coronary Stenting. , 2019, Journal of the American College of Cardiology.

[38]  P. Serruys,et al.  Long-term ticagrelor monotherapy versus standard dual antiplatelet therapy followed by aspirin monotherapy in patients undergoing biolimus-eluting stent implantation: rationale and design of the GLOBAL LEADERS trial. , 2016, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[39]  Claes Held,et al.  Ticagrelor versus clopidogrel in patients with acute coronary syndromes. , 2009, The New England journal of medicine.

[40]  F. Santilli,et al.  Platelet activation in obesity and metabolic syndrome , 2012, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[41]  J. Jakubowski,et al.  In the presence of strong P2Y12 receptor blockade, aspirin provides little additional inhibition of platelet aggregation , 2011, Journal of thrombosis and haemostasis : JTH.

[42]  James E. Tcheng,et al.  2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials , 2018, Circulation.

[43]  P. Serruys,et al.  Effects of Body Mass Index on Clinical Outcomes in Female Patients Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents: Results From a Patient-Level Pooled Analysis of Randomized Controlled Trials. , 2018, JACC. Cardiovascular interventions.

[44]  P. Serruys,et al.  Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions , 2007, Circulation.